To conclude, the STING signaling pathway is widely expressed throughout various cell types, and combining STING agonists with pathogen/cancer cell-specific antigens can provide significant adjuvant effects, including enhanced immune responses based on cytokine secretion and the activation of numerous immune cells (e.g., T cells, macrophages, DCs, and NKs). This evidence concerns the gene STING1 and cancer.